CT measured pulmonary artery to ascending aorta ratio stratified by echocardiographically obtained systolic pulmonary artery pressure values for noninvasive detection of pulmonary hypertension in patients with severe aortic valve stenosis

Fig. 1. Measurement of diameters of interest on axial CT. AA: ascending aorta; PA: main pulmonary artery; red double headed arrow: distance between bifurcation of the pulmonary trunk and level of measurement within main pulmonary artery

Fig. 2. AUROC analyses of PA/AA-ratio for prediction of sPAP ≥ 40, 45 and 50 mmHg with concerning cut-off values, Youden Index, sensitivity and specificity

Fig. 3. AUROC analyses of PA/AA-ratio for prediction of TRVmax ≥ 2.9 and ≥ 3.4 m/s with concerning cut-off values, Youden Index, sensitivity and specificity

Fig. 4. Flow chart of study inclusion and exclusion criteria (created with BioRender.com)

Fig. 5. Kaplan–Meier curves for detection of 1-year survival in dependence of different sPAP cut-off values; a sPAP ≥ 40 mmHg; b sPAP ≥ 45 mmHg; c sPAP ≥ 50 mmHg

Fig. 6. Kaplan–Meier curves for detection of 1-year survival in dependence of different TRVmax cut-off values; a TRVmax ≥ 2.9 m/s; b TRVmax ≥ 3.4 m/s

Fig. 7. Kaplan–Meier curve with corresponding numbers at risk for detection of 1-year survival in dependence of a PA/AA-ratio cut-off value ≥ 0.80

Fig. 8. Serum concentrations of BNP, cTnI, sST2, GDF-15, H-FABP, IGF-BP2 and suPAR in patients with a PA/AA-ratio ≥ 0.80 and with a PA/AAratio ≥ 0.80; *p ≤ 0.05; **p ≤ 0.01; ***≤ 0.001

Fig. 9. AUROC analyses of BNP, cTnI GDF-15, H-FABP, IGF-BP2 and suPAR for prediction of a PA/AA-ratio ≥ 0.80

Fig. 10. Two-way biomarker combinations with corresponding AUROC analyses

Fig. 11. Three-way biomarker combinations with corresponding AUROC analyses

Fig. 12. AUROC analyses of PA/AA-ratio with cardiovascular biomarker cut-off values for prediction of sPAP ≥ 40 mmHg with concerning cut-off values, Youden Index, sensitivity and specificity